| scholarly article | Q13442814 |
| P50 | author | Shahid Punwar | Q60955500 |
| Vincenzo Di Marzo | Q29642556 | ||
| P2093 | author name string | A S Rice | |
| W P Farquhar-Smith | |||
| G Ambrosino | |||
| P Beaulieu1 | |||
| T Bisogno1 | |||
| P2860 | cites work | Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function | Q48262881 |
| Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity | Q48337260 | ||
| Cannabinoid CB1 Receptor Expression in Rat Spinal Cord | Q56827591 | ||
| Nerve growth factor in the synovial fluid of patients with chronic arthritis | Q68058885 | ||
| Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist | Q72302099 | ||
| Optimal scoring strategies and weights for the formalin test in rats | Q73232222 | ||
| Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat | Q74482494 | ||
| SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity | Q77691011 | ||
| Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | Q24309438 | ||
| The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain | Q28236298 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| An analgesia circuit activated by cannabinoids | Q28284331 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice | Q28343324 | ||
| HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor | Q28343769 | ||
| The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) | Q28343961 | ||
| Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor | Q28369714 | ||
| Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide | Q28370516 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| The cloned capsaicin receptor integrates multiple pain-producing stimuli | Q29547511 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. | Q34066911 | ||
| Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide | Q34309026 | ||
| SR141716A, a potent and selective antagonist of the brain cannabinoid receptor | Q34332716 | ||
| N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation | Q34390917 | ||
| 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. | Q34472174 | ||
| Control of pain initiation by endogenous cannabinoids. | Q34749934 | ||
| The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. | Q35029262 | ||
| The formalin test: an evaluation of the method | Q35555523 | ||
| Interactions between synthetic vanilloids and the endogenous cannabinoid system | Q40997351 | ||
| Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes | Q41128302 | ||
| Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors | Q42014580 | ||
| Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells | Q42148717 | ||
| SR141716A is an inverse agonist at the human cannabinoid CB1 receptor | Q42445979 | ||
| Biphasic effects of anandamide | Q43332781 | ||
| The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats | Q43674677 | ||
| Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats | Q45111719 | ||
| Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors | Q47626156 | ||
| SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice | Q47628019 | ||
| The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain | Q47718443 | ||
| Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice | Q47994629 | ||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 85-92 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. | |
| P478 | volume | 396 |
| Q44345700 | A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation |
| Q37115263 | A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase |
| Q43511723 | Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception |
| Q35545219 | Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models |
| Q40174517 | Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors |
| Q33953174 | Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. |
| Q46713327 | Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions |
| Q44342755 | Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors |
| Q43950277 | Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors |
| Q33900873 | Cannabimimetic fatty acid derivatives in cancer and inflammation |
| Q28361058 | Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation |
| Q43543029 | Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit |
| Q35421957 | Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception |
| Q34659433 | Descending control of pain |
| Q37611106 | Dynamic regulation of the endocannabinoid system: implications for analgesia |
| Q48433166 | Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain |
| Q43270083 | Effects of intra-basolateral amygdala administration of rimonabant on nociceptive behaviour and neuronal activity in the presence or absence of contextual fear |
| Q36711160 | Endocannabinoid mechanisms of pain modulation |
| Q36912778 | Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain |
| Q38154691 | Endocannabinoid system and pain: an introduction |
| Q34099017 | Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders |
| Q34167541 | Endocannabinoids and related fatty acid derivatives in pain modulation |
| Q37359261 | Excitation of cutaneous C nociceptors by intraplantar administration of anandamide |
| Q35189004 | Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice |
| Q35995720 | In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. |
| Q35013497 | Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain |
| Q41832173 | Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors |
| Q41693823 | Involvement of the endocannabinoid system in attentional modulation of nociceptive behaviour in rats |
| Q34247711 | Modulation of pain transmission by G-protein-coupled receptors |
| Q41140010 | Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model |
| Q38185075 | No more pain upon Gq-protein-coupled receptor activation: role of endocannabinoids |
| Q34185013 | Pharmacokinetics and pharmacodynamics of cannabinoids |
| Q78727774 | Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects |
| Q34028098 | Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase |
| Q37207245 | Role of cannabinoids in the management of neuropathic pain |
| Q35035850 | Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives |
| Q41584525 | The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors |
| Q34612917 | The endocannabinoid system and pain |
| Q28366593 | The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain |
| Q36341688 | The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids |
| Q74501955 | [The pharmacology of cannabinoid derivatives: are there applications to treatment of pain?] |
Search more.